IMPORTANCE Despite the unquestionable effectiveness of anti-vascular endothelial growth factor therapy (VEGF), there is ongoing controversy about potential systemic adverse effects. Besides the direct adverse effects of anti-VEGF agents, other factors associated with the injection itself, such as perioperative blood pressure fluctuations, may contribute to adverse events.
H igh-dose systemic intravenous anti-vascular endothelial growth factor (VEGF) therapy with bevacizumab has been associated with severe hypertension and an increase in antiplatelet trialists collaboration events. 1 Anti-VEGF therapy is commonly used to treat numerous retinal conditions and has not shown safety signals in several registered randomized clinical trials. [2] [3] [4] However, these trials were not powered to assess the safety risks of rare systemic events and excluded patients with a recent history of myocardial infarction or cerebrovascular insult. Because of this, there is still considerable controversy regarding the systemic safety of intravitreal anti-VEGF therapy, especially in patients at high risk for cardiovascular disease. Information from meta-analyses for age-related macular degeneration has suggested an increased risk of cerebrovascular events with monthly dosing compared with as-needed dosing. 5, 6 Because of the paucity of information on doseresponse curves with respect to cardiovascular adverse events of anti-VEGF therapy, other, perioperative factors, such as blood pressure rise during the injection, may constitute independent risk factors. In this study, we investigated blood pressure changes during intravitreal injections and whether blood pressure rise is associated with other factors.
Methods

Participants
This was a cross-sectional, observational single-center study that included 201 patients undergoing intravitreal injections between October 2017 and January 2018 at the Department of Ophthalmology at the University Hospital Bern, Bern, Switzerland. The study was performed according to the International Ethical Guidelines for Biomedical Research involving Human Subjects and approved by the ethics review board of Bern, Switzerland. Prior written informed consent was obtained from each patient.
Study Protocol
An automated blood pressure measurement device (Philips Intelli Vue X2, Philips SA Healthcare) was used to obtain blood pressure, pulse rate, and oxygen saturation. Intravitreal injections were performed in a certified operating theater according to Swiss health care regulations under topical anesthesia with tetracaine and with an eyelid speculum. A subgroup of patients, receiving bilateral intravitreal injection during the same appointment, was measured twice. A modified Sheehan anxiety questionnaire 7 was used to evaluate anxiety levels. This questionnaire included queries regarding duration of postoperative eye redness, discomfort, and pain in/around the eye after the last injection, as well as the influence of other patients on anxiety level and time point of maximum anxiety level throughout the visit. Subjective pain experience was assessed by the Numeric Pain Rating Scale, 8 which is an 11-point scale from zero (no pain) to 10 (worst imaginable pain).
Statistical Analysis
All data are presented as mean (SD). Statistical analyses were performed using GraphPad Prism 7.03 software and SPSS, version 21.0 (IBM Corp). Data were compared using a 2-tailed t test, with a confidence interval of 95%. A multivariate regression analysis was performed to identify factors associated with blood pressure rise.
Results
Arterial Blood Pressure and Pulse
Two hundred one participants were enrolled (mean [SD] age, 68 [15] years; 46% female; eTable in the Supplement). Time intervals were measured as time on arrival in the waiting area (T1), time in the preparation room (T2), time during the intravitreal injection procedure (T3), and time on return to the waiting area (T4). On arrival to the clinics, mean (SD) systolic arterial blood pressure was 150/78 (20/14) mm Hg (T1, 30 [5] minutes prior to injection). After preparation for the injection and 5 (2) minutes prior to injection (T2), the mean (SD) systolic blood pressure was 162/83 (24/37) mm Hg; during injection (T3), 168/83 (24/16) mm Hg; and after injection (T4), 157/82 (23/16) mm Hg. There was a significant increase in blood pressure from T1 (baseline) compared with all 3 following measurements, whereof the rise from T1 to T3 was highest with a mean (SD) of 18 (15) mm Hg (P < .001) ( Figure) . Mean (SD) pulse rates were 76 (13) bpm, 78 (13) bpm, 80 (13) bpm, and 78 (13) bpm with a significant increase from T1 to T3 (P = .005) (Figure, A). Changes in systolic blood pressure are summarized in the Table. 9 One hundred forty-four patients (72%) had a systolic blood pressure rise of 10 mm Hg or more; in 93 patients (46%), systolic BP rise was 20 mm Hg or more. There was no change in oxygen saturation.
Subgroup Analysis of Patients With Systolic Blood Pressure Greater Than 200 mm Hg
In total, 23 patients (11%) had a systolic blood pressure greater than 200 mm Hg during the injection procedure. This subgroup of patients had a mean (SD) arterial systolic blood pressure increase from 182 (19) mm Hg to 214 (12) mm Hg, resulting in an increase of 32 (20) 
Key Points
Question Is there an increase of blood pressure during intravitreal injections?
Findings In this prospective study, there was a substantial increase in systolic blood pressure during intravitreal injections in some individuals. About 10% of patients had systolic blood pressure rise to greater than 200 mm Hg.
Meaning Because systolic blood pressure can become substantially elevated during intravitreal injections, future work may be needed to determine whether, in patients at risk for cardiovascular or cerebrovascular events, perioperative blood pressure monitoring or antihypertensive therapy needs to be considered. 
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Second Eye
Fourteen patients received sequential intravitreal injections for both eyes during the same visit. To minimize contamination-mediated complications, the second injection was performed approximately 15 minutes after the first injection. Although the systolic blood pressure was lower for the second injection (eFigure in the Supplement), there was still a significant mean (SD) increase of 14 (15) mm Hg (P = .003).
Regression Analysis
Stepwise forward regression analysis revealed that age (R = 0.262; P < .001) and discomfort after the last injection (R = 0.311; P = .02) were associated with a high systolic blood pressure during the injection. Number of previous injections, Numeric Pain Rating Scale, and visual acuity were not associated with a blood pressure rise or systolic blood pressure greater than 200 mm Hg during the injection.
Discussion
There have been concerns that direct effects of anti-VEGF agents may block systemic VEGF and therefore potentially result in similar adverse effects as seen after systemic administration of anti-VEGF such as thromboembolic events, myocardial infarction, cerebrovascular stroke, hypertension, gastrointestinal perforations, and kidney disease. 10,11 However, other factors, such as perioperative blood pressure rise, may potentially contribute to the adverse events seen during this therapy. In this study, diastolic and systolic blood pressure as well as pulse rate were significantly elevated during the injection procedure compared with measurements taken preoperatively. Most of the blood pressure rise occurred following the preparation of the patient prior to the injection procedure.
For severely elevated blood pressure greater than 180/ 110 to 180/120 mm Hg without any signs of end organ damage, the term hypertensive urgency is used. 12 As such, 63 patients (31%) experienced transient hypertensive urgency during the injection procedure. Studies have shown that hypertensive urgencies are associated with an increased risk for subsequent cardiovascular events in patients with arterial hypertension. 13 Furthermore, the rate of fatal cardiovascular events in these studies after hypertensive urgency was 2% during an observation period of approximately 4 years. The incidence of cardiovascular events after hypertensive urgency is similar to the incidence observed in large randomized clinical trials using anti-VEGF therapy. In our study, there was no association of previous number of injections and blood pressure rise. A post hoc analysis of Protocol T found no significant long-term blood pressure rise in either group after 2 years of continuous anti-VEGF administration 14 and, as such, a direct effect of anti-VEGF seems to be unlikely. Another finding in our study was that patients receiving bilateral injections had a blood pressure rise during both injections. Although the blood pressure rise was greater for the first eye compared with the second eye, these data suggest that there are only moderate conditioning effects.
Limitations
As with all studies, our findings must be considered together with the limitations of this study. First, preexisting hypertension or whitecoat hypertension could not be ruled out. Second, in a prospective cross-sectional study design, even when associations are statistically significant, it is difficult to prove whether these associations are the result of a causal effect.
Conclusions
Follow-up studies of long-term antiplatelet trialists collaboration rates will be needed to confirm whether patients with hypertensive urgency are more prone to develop adverse events. Future work may be needed to determine whether, in patients at risk for cardiovascular or cerebrovascular events, perioperative blood pressure monitoring or antihypertensive therapy needs to be considered. 
